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Abstrak 
(Versi Bahasa Malaysia) 
"Extra- amniotic saline infusion" (EASI) bukanlah satu agen pengguguran yang 
baru, tetapi sebagaimana yang dilaporkan, ia adalah satu kaedah yang selamat 
digunakan. Di sebaliknya, Gemeprost merupakan kaedah yang popular dan kerap 
digunakan tetapi mahal. Pada ketika ini , perbelanjaan rawatan adalah tinggi. 
Dengan sebab itu, sesetengah hospital mencari altematifbagi menggugurkan 
kandungan. 
Tatacara kajian: Berrnu1a dari 1hb. Mac 2001 sehingga 28hb. Februari 2002, 
seramai 91 pesakit "silent miscarriage" telah dipilih secara rawak untuk kedua- dua 
kaedah pengguguran ini, iaitu kaedah EASI atau Gemeprost. Keberkesanan kedua-
dua kaedah ini dibandingkan dari segi kesempumaan pengguguran, jangkamasa 
yang diambil untuk mengalami keguguran, jangkamasa berada di hospital, kos 
rawatan, kesan sampingan dan akhimya penerimaan pesakit terhadap kaedah 
terse but. 
Keputusan: Seramai 91 orang pesakit yang mengalami keguguran senyap 
dimasukkan ke dalam kajian ini , di mana seramai 42 orang pesakit menerima EASl 
sebagai agen pengeluaran jarrin dan yang selebihnya menerima gemeprost 1 mg 
sehari . Keberkesanan cara- cara tersebut dari segi kesempumaan keguguran, 
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tempoh yang diambil untuk merangsang pengguguran, tempoh berada di hospital, 
kesan- kesan sampingan yang berlaku dan kos dibandingkan. Sebanyak 54.8% 
daripada pesakit yang menerima EASI mengalami keguguran sempurna 
berbanding dengan 59.2% di dalam kumpulan gemeprost.Hitung panjang masa 
yang diambil oleh EASI untuk menggugurkan kandungan adalah 12.76 jam 
berbanding dengan 10.24 jam di dalam kumpulan gemeprost. Kedua- dua 
pemerhatian ini adalah tidak relevan dari segi statistik. Tiada perbezaan didapati 
dari segi jangkamasa tinggal di hospital dan kesan sampingan yang dialami. Walau 
bagaimanapun, sepertimana yang dijangkakan, EASI adalahjauh lebih murah 
berbanding gemeprost bagi setiap pengguguran (RM 69.25 berbanding RM183.30). 
Cadangan: Kaedah EASI didapati sama berkesan dengan Gemeprost, dengan itu 
disarankan kaedah ini digunakan sebagai altematif kepada Gemeprost untuk 
pesakit- pesakit terpilih terutamanya mereka yang berada eli tempat- tempat di 
mana masalah kewangan merupakan faktor penting. 
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Abstract 
(English version) 
Extra- amniotic saline infusion (EASI) as abortifacient is not new, however it is still 
a safe abortifacient as quoted in the literatures. Gemeprost on the other hand is a 
popular abortifacient used widely however at exhorbitant cost. In this day and age 
when the price of health care is escalating some countries are considering cheaper 
altematjves. We at Hospital Kota Bharu wished to evaluate EASI as an alternative 
method of abortifacient. 
Methodology: From 1st March 2000 till 28th February 2001 , 91 patients were 
randomly selected to two methods of abortifacient, Gemeprost 1 mg daily (wruch is 
the standard protocol in HKB) and EASI. Both methods were analysed and 
compared for effectiveness in terms of completeness of abortion and induction-
abortion interval, adverse effects, duration of hospital stay and the cost of treatment 
and finally the patients' satisfaction of the treatment. 
Results: 54.8% of the patients receiving EASI had complete abortion as compared 
to 59.2% in the gemeprost group. The mean duration of induction- abortion interval 
was 12.76 hours in the EASI group and 10.24 hours in the gemeprost group. Both of 
these 2 end- results were not statistically significant. No difference in the duration of 
hospital stay and side- effects were noted. However, it is noted that using EASI is far 
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cheaper than gemeprost, being RM 69.25 and RM183.30 respectively. Majority of 
the patients were satisfied with the treatment, however, 17% of the patients 
receiving EASI were not satisfied with the treatment, whilst none were noted in the 
gemeprost group. 
Recommendation: EASI is as effective as gemeprost as abortifacient in mid-
trimester silent miscarriage provided that the patients were initially explained 
regarding the expected discmfort. We recommend EASI as an alternative to 
gemeprost in selected patients especially in places where financial constrain is an 
important factor. 
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1. Introduction 
WHO estimates that throughout the world, approximately 500 000 women ctie every year 
from pregnancy- related causes. A large proportion of these deaths are attributable to 
complication of abortion. 
Spontaneous miscarriage occurs in 10 to 20 % of clinical pregnancy and amounts for 
50000 in- patient admissions to hospital in United Kingdom annually. Management has 
changed little in the last 50 years and is commonly based on tradition rather than 
evidence- based approach. Until recently, miscarriage has achieved less attention in the 
medical literature than any other pregnancy- related problem. 
Majority of the women with silent miscarriage are referred to the hospital for further 
assessment and subsequently evacuation of the uterine content. This can be achieved via 
several methods, which includes surgical uterine evacuation, medical management as 
well as expectant management. 88% of the referred case will undergo surgical uterine 
evacuation (Penny G. et al, 2000). In a partially randomized study comparing surgical 
and medical evacuation, 20% of the female expressed strong preference for medical 
management. The main reasons given for their choices were "avoidance of general 
anaesthesia" and the feeling of being "more in control" (Penny et al, 2001 ). 
Gemeprost has long being used as abortifacient (Benette et al, 1990, Lim et al, 
1990,Byrne and Onyekwuluje, 1994, Krauss et al , 1994). Being a prostaglandin E 1 
1 
analogue, it stimulates uterine contraction thus causing expulsion of the products of 
conception. The efficacy of gemeprost 1mg given at 3 hourly interval to a maximum of 5 
administrations per day has been published (Byrne and Onyekwuluye, 1994 ). Lower 
dosage of gemeprost had been shown to be as effective as the recommended dose, with 
lesser side- effects (Thong and Baird, 1992, Armatage and Luckas, MJ.,1996). Based on 
these data, Hospital Kota Bharu has been using a lower dosage of gemeprost to induce 
silent miscarriage as the standard abortifacient. 
The need for refrigeration and its exhorbitant price has changed gynecologists' 
perception on this drug. Concern on health economics has inspired the researchers to fmd 
alternative for gemeprost. The recent discovery of misoprostol as abortifacient served this 
purpose. Being in the same group as gemeprost, as effective and at the price of far 
cheaper than gemeprost, misoprostol now is much accepted. However, its vaginal usage 
is not guarantied by the manufacturer neither does it licensed by the FDA of United 
Kingdom (Misoprostol Literature Review, 2001). Due to this, misoprostol is not yet 
accepted by the administration of Hospital Kota Bharu as abortifacient. 
However, whether it is the gemeprost or misoprostol, these drugs are not without side-
effects and complications. The manufacturer has clearly documented the caution usage of 
gemeprost in certain condition like obstructive airway disease, cardiovascular 
insufficiency, elevated intraocular pressure, cervicitis and vaginitis (Misoprostol 
Literature Review, 2001 ). Therefore, alternative, which is much safer should be used in 
these conditions. 
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The usage of extra- amniotic saline infusion (EASI) has long been forgotten without any 
strong and proper reason. It was frrst introduced in 1974 to induce abortion (Halbrecht. 
and Blum, 1974) and 100 percent success rate without any complication was reported. 
This achievement was later repeated by several other authors on cases of silent 
miscarriages and fetal death (Mahomaed and Jayaguru, 1997, Mawire et al, 1999). As 
EASI was proven safe and cheap, Hospital Kota Bharu has adopted this method to induce 
abortion for high risk cases. 
This study was designed to compare the effectiveness, side effects, cost and patients' 
acceptance ofEASI and gemeprost. If it is proven that EASI is as comparable to 
gemeprost, it can be used in place of gemeprost especially where financial constraints are 
an important factor. 
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2. Literature review 
2.1. Terminology 
. The term abortion does not differentiate between spontaneous abortion and induced 
abortion. Therefore many gynaecologists refer the former as "miscarriage". Abortion 
and other inappropriate terminology (e.g. : "pregnancy failure", "abnormal 
pregnancy", etc.) may contribute to the development of negative self- perception in a 
group of women already feeling a sense of failure and perhaps shame, guilty and 
insecurity (Chalmers, 1992). In 1997, a Study Group of The Royal College of 
Obstetricians and Gynaecologists recommended that traditional medical terminology 
should be changed (for example:"miscarriage" replacing "spontaneous abortion", 
" incomplete miscarriage" replacing " incomplete abortion" and "silent miscarriage" 
replacing "missed abortion" (Recommendations from 33rd RCOG Study group, 
1997). Alternative terminology for the later include "delayed mjscarriage" or "early 
fetal demise". 
2.2. Definition 
Familiarity with the local legal definition is mandatory because there is considerable 
state- to- state variation. In Uruted Kingdom, miscarriage is defined as pregnancy 
loss occurring before 24 completed weeks of gestation (Llewelyn- Jones et al , 1999). 
United States of America however, defined it as termination of pregnancy before the 
20th gestational week (Gant and Cunningham, 1993). Because of the different 
definitions of viability in different countries, the World Health Organization (WHO) 
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has recommended that a fetus is viable when gestational period has reached 22 or 
more weeks or when the fetus weighs 500 grams or more (Llwelyn- Jones et al, 
1999). 
Malaysia at the moment is defining it as pregnancy loss occurring before 24 
completed weeks of gestation, equivalent to expulsion of fetus weighing 500 gram or 
less. 
2.3.Varieties of miscarriage 
For descriptive purposes the miscarriage is classified according to the findings when 
the women are frrst examined, but one kind may change into another if the 
miscarriage process continues. If infection complicates miscarriage, the term septic 
miscarriage is used. Below are the descriptions of various types of miscarriage: 
a) Threatened Miscarriage 
Threatened Miscarriage refers to intra- uterine bleeding less than 24th week of 
gestation, with or without uterine contraction, without cervical dilatation, and without 
expulsion of products of conception. It may or may not be accompanied by mild 
cramping pain resembling dysmenorrhoea or by low backache. Ultrasound therefore 
must reveal the fetus to show signs of life (e.g. presence ofheartbeat or motion). 
Other causes of bleeding in early pregnancy should be excluded. Of those women 
who bleed in early pregnancy, only one half or even less actually abort 
(Recommendations from the 33rd RCOG Study Group, 1997). Bleeding in threatened 
miscarriage is frequently slight, but it may persist for days or weeks. Unforttmately, 
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an increased risk of suboptimal pregnancy outcome in the form of prematurity, low 
birth weight, and perinatal death persists. However, the risk of birth of a malformed 
infant does not appear significant. It is no longer a normal practice to insist that the 
women must stay in bed until the bleeding ceased. However, if the women feel more 
comfortable to be there, she may do so. 
b) Inevitable miscarriage 
Inevitable miscarriage is intra-uterine bleeding less than 24th week of gestation, with 
continued cervical dilatation but without expulsion of products of conception. 
Miscarriage is considered inevitable with 2 or more of the following criteria's 
(Llewelyn- Jones et al, 1999): 
i) moderate effacement of the cervix 
ii) cervical dilatation more than 3 em 
iii) rupture of membranes 
iv) bleeding more than 7 days 
v) persistence of cramps despite narcotic analgesia 
vi) signs of termination of pregnancy (e.g.: absence of mastalgia) 
Inevitable miscarriage may follow signs of threatened miscarriage or more 
commonly, starts without warning. Soon after the onset of inevitable miscarriage, the 
miscarriage occurs either completely or incompletely. In most cases, the miscarriage 
is incomplete. 
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c) Incomplete Miscarriage 
Incomplete miscarriage is expulsion of some but not the entire products of conception 
less than 24th weeks of gestation. The fetus and the placenta are likely to be expelled 
together in miscarriages occurring before tenth week, but separately thereafter ( Gant 
and Cunningham, 1993). When the placenta in whole or in part is retained in the 
uterus, bleeding ensues sooner or later to produce signs of incomplete miscarriage. 
With more advanced gestational age, bleeding may be more profuse and may 
occasionally be massive to the point of producing profound hypovolaemia. If the 
placenta is partly separated and partly attached, the splint- like action of the attached 
portion of the placenta interferes with myometrial contraction in the immediate 
vicinity. The vessels in the denuded segment of placental site, deprived of 
constriction provided by contraction and retraction of the myometrium, bleeds 
profusely. 
d) Complete Miscarriage 
Complete miscarriage is expulsion of all products of conception less than 24th weeks 
of gestation when the entire conceptus has been expelled, pain ceases, but slight 
spotting persists for a few days. Ultrasound shows an empty uterus (or one containing 
less than 10 mm of tissues or blood clots) (Chipchase and James, 1997). 
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e) Septic Miscarriage 
Septic miscarriage is less common nowadays, because of better care and fewer 
"backyard" abortion. Infection complicating either spontaneous or induced 
miscarriage is usually mild and is localized to the uterus. However septic miscarriage 
induced by criminal abortion usually involved endogenous organisms, most 
commonly anaerobic streptococci which may spread to the fallopian tubes, cervix, 
parametrium or other pelvic cellular tissue and later causing peritonitis. 
f) Silent miscarriage 
Silent miscarriage is death of embryo or fetus less than 24th week of gestation, but the 
product of conceptus are retained in utero. 
If the embryo dies in the early weeks, it is likely to be anembryonic or blighted. In 
other cases a fetus fonns but die. Multiple haemorrhage may occur in the 
choriodecidual space, which bulge into the empty amniotic sac. This condition is 
called carneous mole (figure 1). 
2.4.lncidence of miscarriage 
The incidence of spontaneous miscarriage is between 15 and 20% of all clinically 
diagnosed pregnancies. However, the actual loss maybe as high as 60% of 
"chemical" pregnancy diagnosed before the first missed period by estimation of the 
f3- HCG (sub- clinical or undiagnosed spontaneous miscarriage) (David et al, 1999). 
8 
Figure 1: Carneous mole- a small fetus can also be seen in the center 
2.5.Aetiology of miscarriage 
The causes of miscarriage may be classified depending on the aetiological defect, 
which may relate to the fetus, placenta and maternal condition. 
a) Fetal causes of spontaneous miscarriage 
i) chromosomal abnormality (eg: trisomy16, 22, 21 and 15) 
ii) structural abnormality ( eg: neural tube defect) 
b) Abnormalities of implantation 
c) Uterine causes of miscarriage 
i) submucosal fibroids 
ii) fusion abnormality of the uterus 
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iii) cervical incompetence 
d) maternal diseases 
i) maternal illnesses such as poorly controlled ctiabetes mellitus, thyroid 
disease, SLE, Von Willebrand Disease and anti- phospholipids syndrome. 
ii) Maternal infection such as syphilis, rubella, herpes simplex, toxoplasmosis 
and cytomegalovirus infection. 
e) Undetennined causes 
2.6.Diagnosis and investigations 
2.6.1. Estimations of serum f3-hCG 
The majority of patients attending the gynaecology ward can be managed 
using ultrasound scan. However, in some cases, there is difficulty in 
diagnosing some cases of early pregnancy and early ectopic pregnancy 
and its potentially serious implications. In such situation, estimation of 
serum 13- hCG is essential. 
2.6.2. Ultrasound diagnosis 
Traditionally much reliance was placed on the clinical history and the 
pelvic examination but these are unreliable, perhaps none more so than 
menstrual dating. Ultrasound has become the main means of primary 
categorization. Even though clinical features do provide important 
additional information, the history and examination can be tailored to the 
needs of the individual patient according to the scan findings. With the 
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introduction of transvaginal ultrasound, longitudinal assessment of early 
pregnancy can be made in terms of viability and growth. 
The Joint Working Party of Royal College of Radiologists (RCR) and the 
Royal College of Obstetric and Gynaecology (RCOG) in 1995 had advised 
that the documentation of early pregnancy scans should be standardized as 
shown below: 
Table 1: RCRI RCOG guidelines for ultrasound in early pregnancy 
(minimal data set). 
• Gestational sac number, size and quality 
• Presence/ absence of fetal yolk sac 
• Fetus number, size (crown- rump length) and cardiac 
activity 
• Intrauterine haematoma 
• Adnexallesion 
• Peritoneal fluid 
Documentation of an intrauterine pregnancy can be made consistently at the 
end of 5th menstrual week by identification of the gestational sac within the 
uterus. This structure is anechoeic, but it has a characteristic highly echogenic 
border that represents the decidual reaction. Development milestones seen by 
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transabdominal ultrasound scanning in the first trimester of pregnancy are 
summarized below: 
a) Gestational sac 5-6 weeks 
b) Fetal pole 6-7 weeks 
c) Cardiac activity 7-8 weeks 
d) Somatic activity 8-9 weeks 
e) Placenta 9-10 weeks 
f)BPD 12 weeks 
Ultrasound plays a major role in maternal assurance, where fetal cardiac 
activity is seen and is pivotal in the assessment of early pregnancy 
complication such as vaginal bleeding. However, there are limits to the 
ultrasound resolution of normal early pregnancy development. Advice by 
The Joint Working Party of Royal College of Radiologists (RCR) and 
RCOG produced in 1995 concluded that a diagnosis of miscarriage should 
not be made if no fetal pole is seen and the gestational sac diameter is less 
than 20mrn, or if the visible fetal pole is less than 5mm, as only 65% of 
normal embryo will display detectable cardiac activity at this stage. 
Repeat ultrasound after at least a week is recommended, and if features are 
unchanged, this is diagnostic of pregnancy loss. 
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2. 7. Treatment of miscarriage 
The technique of evacuation of products of conception employed will depend on a 
number of factors, the most important being the duration of pregnancy and the 
preference of the gynaecologist carrying out the operation. The duration of 
pregnancy can be divided according to the gestation, that is: 
a) very early abortion 
b) 1st trimester abortion 
c) 2nd trimester abortion 
Removal of products of conception for 2nd trimester pregnancy is more difficult, 
has a higher complication rate, and may require subsequent curettage under 
anaesthesia to complete uterine evacuation. 
2. 7. I . Surgical uterine evacuation for miscarriage 
Since the 1 800s surgical uterine evacuation has been the standard 
treatment offered to women who miscarry. This is based on an assumption 
that retained tissue increases the risk of infection and haemorrhage. 
However, the introduction of surgical infection occurred at a time when 
illegal abortion was common and antibiotics were not available. It remains 
the treatment of choice if bleeding is excessive, if vital signs are unstable 
or when infected tissue is present in the uterine cavity. Studies suggest that 
less than 1 0% of women who miscarry fall into these categories (Ballargh 
et al , 1998). 
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Sharp/ blunt curettage and suction curettage have been used for delayed 
mjscarriage. Serious complications of surgery include perforation, cervical 
tears, intra- abdominal trauma, intra- uterine adhesions and haemorrhage. 
In all cases where surgery is being considered the need for cervical 
ripening should be assessed. 
2.7.2. Expectant management for miscarriage 
Expectant management has been accepted as alternative technique, 
although it has not replaced surgical evacuation. Obse_rvational and 
controlled trials of expectant management in patients with spontaneous 
miscarriage versus surgical management showed wide variations in 
reported efficacy ofthe expectant management, i.e. 25 to 100 percent 
(Nielsen and Hahlin, 1995, Chipcbase and James, 1997, Hurd et al, 1997, 
Jurkovic et al, 1998). 
Various ultrasound criteria were used to defi.ne "retained products" at 
study entry. Nielsen and HahJin (1995) included patients with AP tissue 
diameter of 15-50mm with ultrasound review at 3 days (efficacy 71 %). 
Chipchase and James (1997) included all those with an AP tissue diameter 
ofless than 50mm and reviewed patients clinically on three occasions up 
to 6 months (efficacy 100% ). However, the mean tissue diameter managed 
expectantly was only 11mm. These would have been defined as "complete 
miscarriage" by Nielsen and Hahlin (1995) and excluded from his study. 
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When ultrasound assessment of uterine cavity shows heterogenous 
shadows with a maximum AP diameter of 15mm or less, genuine retained 
products are much less likely to be confirmed histologically (Rulin et al, 
1993). 
2. 7.3. Medical management for miscarriage 
Although the medical management of miscarriage with herbal remedies 
was known before the 19th century, only in the last decade of the 20th 
century has interest in this field been rekindled (Hinshaw, 1997). As well 
as avoiding complications of surgery, it is also less expensive than surgery 
(Hughes et al, 1996). 
Various efficacy rate for th.is type of management has been cited. Factors 
determining the success rate of the treatment include type of miscarriage, 
gestational age, type, dose and route of administration of the medication 
and whether ultrasound scan was used to access completeness of abortion. 
The available drugs used for medical management of mid- trimester silent 
miscarriage include anti-progesterone, mifepristone and various types of 
prostaglandin analogues such as sulprostone, gemeprost and misoprostol. 
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a) Mifepristone 
Mifepristone (RU486) is a liB- dimethyl- amino- phenyl derivative of 
norethidrone. It has a high affinity for progesterone and glucocorticoid 
receptors (Mahajan and London, 1997). Receptor binding in the 
placenta is followed by inefficient transcription of progesterone 
receptors in the deciduas, myometrium and cervix and thus causing 
termination of the pregnancy. 
If used alone, the success rate of mifepristone to cause complete mid-
trimester abortion is about 60% to 65% (Sitruk- Ware, 1990, The RU 
486 Collaborative Group, 1990). However, its effectiveness increases 
dramatically to 94 to 96% if used in combination with prostaglandin 
(eg: gemeprost) (Grimes et al, 1988, Couzinet et al, 1986). It was 
reported that 5% to 15% of those cases induced with mifepristone need 
to undergo dilatation and curettage (D&C) to achieve complete 
abortion (Ch~ 1993). 
The recommended dose of oral mifepristone is 600mg followed by 
1 mg of gemeprost given 48 hours later. However, subsequent studies 
have shown that a lower dose of mifepristone (200mg) is equally 
effective (Penny et al, 1995, Baird et al, 1995). 
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Various side effects were reported with the use ofmifepristone. 
Infection mainly involving the pelvic and genjtal tract was reported to 
be one of the commonest adverse affect seen (Hill, 1990, Rodger et al, 
1987) and was thought to be due to the suppression of immune system 
brought by tills drug (Schulster, 1976). 79.1% of the patients bad 
severe uterine cramps and 80.5% needed strong analgesia (Norman, 
1991). Excessive bleeding per vaginum was also noted and tbjs was 
attributable to the nature of expulsion of the fetus (Hill et al, 1990, 
WHO, 1990, WHO task force, 1993). 
b) Gemeprost 
Gemeprost is a Prostaglandin E1 analogue with the chemical name of 
16, 16- dimethyl- trans- delta 2- PGE1 methyl ester, with the below 
structure: 
• OH 
Figure 2: The structure of gemeprost 
It has a role for induction of abortion, ripening of the cervix and as 
. I 1 nd a post- partum haemostat1c agent. ts ro e as 2 trimester 
abortifacient has been widely published (Krauss et al, 1994, Byrne 
and Onyekwuluje, 1994, Querido and Haspels, 1990, Cameron et 
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al, 1987). It stimulates uterine contraction by binding to specific 
receptors on the myometrial-cell surface. This action results in 
increased calcium production by the endoplasmic reticulum and, 
consequently, in uterine contraction causing expulsion of the POC. 
Gemeprost was reported to be effective in terms of completeness 
of abortion in 86% to 91% of the cases of mid- trimester silent 
miscarriage with the mean induction- abortion interval of 11 to 14 
hours (Le Roux et al, 2001, Gemzell- Danielsson and Ostlund, 
2000, Wong et al, 1998). The high efficacy is associated with 
increase adverse effects. In a randomised trial, where 1 mg versus 
0.5 mg ofGemeprost at 3 hours interval was compared, the 
complete miscarriage rate was similar for the 2 groups (98% -
100% ), although the incidence of adverse effects were significantly 
lower in the later group (Rodger et al, 1987). The recommended 
dosage for gemeprost at the moment is 1 mg given at 3 hours 
interval for the maximum of 5 administrations in a day. 
Cameron et al (1987) reported that 82% of the cases aborted within 
24 hours with the mean induction- abortion interval of 881 minutes 
± 31 minutes. Querido and Haspels in 1990 showed that 58.9% of 
their patients aborted after one administration of gemeprost 
(aborted within 12 hours after the initial insertion). They 
18 
a) 
b) 
c) 
d) 
e) 
f) 
g) 
h) 
i) 
j) 
k) 
I) 
considered the method fail if patients still not aborted within 24 
hours. 32.1% of them failed to abort despite 5 administrations of 
gemeprost. Side- effects were noted in 58.9% of the cases but no 
serious side- effects were encountered. 
The known side- effects of gemeprost are as below: 
vaginal bleeding 
uterine cramp and pain 
nausea and vomiting 
loose stool 
headache 
muscle weakness 
dizziness 
flushing 
chills 
backache 
chest pain 
mild pyrexia 
m) uterine rupture 
Byrne and Onyekluwuje (1994) reported that retained placenta was 
the commonest side- effect encountered (85% ), followed by nausea, 
diarrhoea and vomiting (25%, 15% and 10% respectively). 
Abdominal cramp was seen after 275 minutes of gemeprost 
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administration in which 79% needed pain relief and 80% of these 
cases required parenteral opiate. Serious side- effect (uterine rupture) 
has been reported (Thong et al, 1995, Norman, 1995). This rare 
complication occurred especially in multiparity and those with 
previous uterine surgery. 
c) Sulprostone 
Sulprostone is a Prostaglandin E2 analogue which has the chemical 
name of 15- methyl PGF2a. It is 10 times more potent than gemeprost 
It is available in an infusion form at the dosage of 1 OOOJ.Lg diluted in 
500 mls of normal saline given at 10 hours infusion or 500J.Lg by slow 
infusion over 10 hours (Marpeau et al, 1993). Its effectiveness 
(expulsion of POC within 24 hours) has been reported to range from 
63% to 93% (Biswas and Roy, 1996, Waner et al, 1994, Maria and 
Matheron, 1994, Marpeau et al, 1993). All abortions were achieved 
within 24 hours with the mean induction- abortion interval of 14 hours. 
Minimal side- effects, which include diarrhoea and vomiting, were 
observed in all cases. Marpeau et al ( 1993) reported 3 cases, which 
needed laparotomy for haemorrhagic syndrome and reported a case 
of uterine rupture with this agent. In April 1991, the first death of 
medical termination of pregnancy was reported in which a 3 7year old 
French woman who was a Para 12 and had 1 previous abortion died of 
heart attack after injection of sulprostone (Anon, 1991 ). Since this 
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incident, extra caution was taken in terminating pregnancy and the 
safety of medical and surgically induced abortion was compared. 
d) Misoprostol 
Misoprostol is a prostaglandin Et analogue indicated for prevention 
and treatment of gastric and duodenal ulcer resulting from long- term 
non- steroidal anti- inflammatory drug use. It is produced by Searle 
Pharmaceuticals under the product name Cytotec® and is available in 
most countries. The Obstetrics and gynaecological application for 
which misoprostol- only regimens are being evaluated include 1st and 
2nd trimester abortion, treatment of miscarriage, cervical priming, 
induction of labour and prevention and treatment of post- partum 
haemorrhage (SOGC Clinical Practice Guidelines, 2001 ). 
Being a synthetic analogue of prostaglandin E1, it causes increase in 
the uterine contractility and therefore causing expulsion of the POC. 
Among the key advantages of misoprostol as abortifacient is its 
effectiveness, low cost, stability (tablets have a shelf half life of 
several years at room temperature), accessibility and its potential to 
lead to safer reproductive health outcomes than the currently used 
therapies (Misoprostol Literature Review, 2001). Its uterotonic 
properties is enhanced if women are pretreated with mifepristone, 
reflecting the effect of anti- progesterone in increasing sensitivity to 
prostaglandin. When misoprostol is used in combination with 
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mifepristone, the vaginal route has been shown to be superior to the 
oral route (95% versus 87%, respectively) (El-Refaey et al, 1995). The 
incidence of adverse effects was also reduced in the former group. 
This is an unlicensed use ofmisoprostol and should be emphasized to 
patient prior to its administration (British Medical Society and Royal 
Phamarceutical Society of Great Britain, 2000). 
Medical management of abortion maybe less suitable for those women 
with heavy vaginal bleeding, anaemia (Hb less than 10 g/dl) or who are 
pyrexial and who have contraindication to medical therapy (table 2). 
Table 2: Contraindications to medical induction of labour 
Absolute contraindications: 
· Pregnancy.·more than 63 days 
Suspected ectopic pregnancy · 
Adrenal insufficiency 
Long term glucocorticoid therapy 
Haemoglobinopathy or on anti- coagulant therapy 
Anaemia 
Known allergy to mifepristone or prostaglandin 
Smokers over 35 years of age 
Porphyria 
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Relative contraiodications: 
Hypertension 
Severe asthma 
2.7.4 . Mechanical management for miscarriage 
The mechanical methods of abortifacient include foley catheter (with or 
without extra- amniotic saline infusion), natural dilators ( eg: larninaria) 
and synthetic dilators. 
The mechanism of action of this method is by dilating the cervix through 
mechanical pressure and increase prostaglandin production thus causing 
expulsion of the POC (Keirse et al, 1983, Boulvain et al, 2000). 
For pregnancy around and after the 3rd month, the intrauterine introduction 
of a urinary catheter or a similar flexible device is the technique used in 
most places. In Latin America it is called the sonda. The introduction of 
the foreign body causes release of the prostaglandin and induces uterine 
contraction and expulsion of products of conception 1 to 2 days after 
insertion of the foreign body. 
The variation of the above method is by using extra-amniotic saline 
infusion. This method was first introduced by Halbrecht and Blum in 1974 
as a variation of inducing abortion using intra- or extra- amniotic injection 
of prostaglandin which has unpleasant side- effect and intra- amniotic 
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injection of various hypertonic solution which have frequent 
complications and maybe serious. 
A self- retaining bladder catheter ending in a balloon is passed through the 
cervix, the balloon is inflated with sterile water to hold the catheter in 
place and an extra- amniotic injection of saline is made continuously using 
some form of drip or pump, as in figure 3. 
II Normal saline II 
) 
~~c==~ 
Figure 3: Diagramatic figure showing EASI as abortifacient 
The mechanism of abortion with extra- amniotic saline infusion is unclear. 
It is postulated that the mechanical separation of membrane by instillation 
of the saline induces a rise in local endogenous prostaglandin, which is 
responsible for the onset of the uterine contraction. Human studies have 
measured increased prostaglandin concentrations in amniotic fluid and 
maternal plasma during balloon- induced cervical ripening. Chandra et al 
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